Lupin signs agreement with Gan & Lee Pharmaceuticals for a novel GLP-1 receptor agonist
News by Aliceblue News Desk
30 Dec 2025
Introduction
Leading pharmaceutical company signed an exclusive agreement to commercialize and distribute Bofanglutide, a fortnightly GLP-1 receptor agonist, in India for treating type 2 diabetes and managing obesity.
Also Read: Va Tech Wabag: Gets large Saudi order for 50 MLD BWRO worth up to ₹600Cr
Share price movement of Lupin
On December 30, 2025, Lupin Ltd opened at ₹2,098.95, up 0.94% from its previous close of ₹2,079.50. The stock reached a high of ₹2,099.60 (0.96%) and a low of ₹2,077.00 (-1.04%). By 11:36 AM, it traded at ₹2,079.70, a 0.01% increase, with a market cap of ₹95,000.45 crore.
Lupin Signs India Rights for Bofanglutide
Lupin Limited announced an exclusive licensing, supply, and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist for diabetes and obesity management.
Bofanglutide is designed for adults with type 2 diabetes and overweight or obese individuals. The injection reduces blood glucose and body weight while offering fortnightly dosing.
Under the agreement, Lupin will have exclusive rights to commercialize and distribute Bofanglutide in India, strengthening its diabetes portfolio and expanding presence in the obesity treatment segment.
Stock performance of Lupin for Period of 1 week, 6 months, and 1 year
Lupin Ltd delivered a -1.49% return over the past week, gained 6.51% over the past six months, and declined 9.92% over the past one year.
Also Read: Ola Electric shares in focus after firm ramps up deliveries of 4,680 Bharat Cell Vehicles
Shareholding pattern of Lupin
| Particulars | Sep 2025 | Jun 2025 | Mar 2025 |
| Promoter | 46.90% | 46.90% | 46.90% |
| FII | 21% | 21% | 21.50% |
| DII | 26.60% | 25.60% | 25.40% |
| Public | 6.10% | 6.30% | 6.20% |
About Lupin
Lupin Limited (NSE: LUPIN) is a global pharmaceutical leader headquartered in Mumbai, offering branded and generic formulations, complex generics, biotechnology products, and APIs, with 15 manufacturing sites, 7 research centers, and over 24,000 employees.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Lupin Limited share price going up today?
A: Lupin Limited share price is in focus after signing an exclusive India licensing agreement with Gan & Lee Pharmaceuticals for Bofanglutide.
Q: What does Lupin Limited specialize in?
A: Lupin Limited specializes in branded and generic pharmaceuticals, complex generics, biotechnology products, active pharmaceutical ingredients, and healthcare solutions globally.
Q: What is the 52-week high and low of Lupin Limited stock?
A: Lupin Limited stock recorded a 52-week high of Rs 2,403.45 and a 52-week low of Rs 1,774.00.
News Author
Aliceblue News Desk
